Intellia Therapeutics Inc (NTLA) concluded trading on Wednesday at a closing price of $8.87, with 4.22 million shares of worth about $37.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.39% during that period and on April 30, 2025 the price saw a gain of about 8.17%. Currently the company’s common shares owned by public are about 102.03M shares, out of which, 97.42M shares are available for trading.
Stock saw a price change of 9.64% in past 5 days and over the past one month there was a price change of 24.75%. Year-to-date (YTD), NTLA shares are showing a performance of -23.93% which decreased to -57.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.90 but also hit the highest price of $28.18 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 3.39 million. The stock is currently trading 18.10% above its 20-day simple moving average (SMA20), while that difference is up 1.22% for SMA50 and it goes to -41.42% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 102.03M outstanding shares and institutions hold larger chunk of about 92.58% of that.
The stock has a current market capitalization of $918.20M and its 3Y-monthly beta is at 2.34. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 5.77 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 6.59% while standing at 9.92% over the month.
Stock’s fiscal year EPS is expected to rise by 10.69% while it is estimated to increase by 5.60% in next year. EPS is likely to grow at an annualized rate of 23.52% for next 5-years, compared to annual growth of -20.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on April 21, 2025 offering an Outperform rating for the stock and assigned a target price of $21 to it. Coverage by H.C. Wainwright stated Intellia Therapeutics Inc (NTLA) stock as a Buy in their note to investors on March 05, 2025, suggesting a price target of $30 for the stock. On February 28, 2025, JP Morgan Downgrade their recommendations, while on February 28, 2025, Goldman Downgrade their ratings for the stock with a price target of $9. Stock get an Equal-weight rating from Morgan Stanley on January 27, 2025.
